Cyclic Peptide Nanotubes Combat Chemotherapy Resistance

A research team at CiQUS (University of Santiago de Compostela, Spain) has developed an innovative molecular strategy with the potential to overcome chemotherapy resistance. This significant study centers on doxorubicin, a commonly utilized chemotherapy drug that often leads to the emergence of resistant cancer cells, posing a major challenge in oncology. The findings have been published in ACS Applied Materials & Interfaces in 2025.

Mechanism of Action

The approach articulated by the researchers hinges on a fundamental yet powerful concept: the utilization of cyclic peptides, which are small rings of amino acids that can self-assemble into hollow cylindrical structures known as nanotubes. These nanotubes are designed to adhere to cancer cell membranes, thereby facilitating the delivery of doxorubicin directly to the nucleus of tumor cells, where it can exert its therapeutic effects.

Prolonged exposure to doxorubicin is known to induce cellular mechanisms responsible for drug resistance. The team, led by Juan R. Granja, has ingeniously coupled doxorubicin to these peptides, allowing the therapeutic agent to bypass the cellular resistance mechanisms that typically deactivate it. This bypass is crucial, as many tumors develop the ability to actively expel chemotherapy drugs, which significantly diminishes their efficacy.

Key Findings

Noteworthy findings from the experimental studies indicated that:

• Cancer cell membranes possess a higher concentration of negatively charged lipids compared to healthy cells.
• The cyclic peptides exhibit a strong affinity for these anionic surfaces, which facilitates their effective interaction with cancer cell membranes.
• The structure of the cyclic peptide is critical for the stability and formation of nanotubes, which enhances their capacity to penetrate malignant cells.

As a result, peptide–drug conjugates successfully infiltrate resistant cells and progress toward the nucleus, where doxorubicin intercalates with DNA, triggering its cytotoxic action.

Comparative Effectiveness

In comparison to traditional delivery methods, this new strategy provides the following advantages:

Implications for Future Cancer Treatment

The implications of these findings are profound, potentially paving the way for new combination therapies where peptide-based nanotechnology could serve as an invaluable ally against cancer. By integrating selectivity, efficient drug transport, and controlled release mechanisms, this approach not only aims to enhance chemotherapy efficacy against resistant tumors but also aspires to inspire the creation of new therapeutic strategies for challenging oncological cases.

“This study highlights the potential to utilize peptide nanotubes as highly efficient delivery vehicles capable of overcoming one of the major barriers to effective cancer treatment: drug resistance.” – Marcos Vilela-Picos, Lead Researcher

Conclusion

In conclusion, the innovative use of cyclic peptide nanotubes represents a promising advancement in the field of oncology. By efficiently delivering doxorubicin to drug-resistant cancer cells, this approach may significantly enhance treatment outcomes and provide new hope for patients afflicted with hard-to-treat tumors.

For more information, refer to the original study: Self-Assembling Cyclic Peptide Nanotubes for the Delivery of Doxorubicin into Drug-Resistant Cancer Cells, ACS Applied Materials & Interfaces (2025).

References

[1] Vilela-Picos, M., et al. (2025). Self-Assembling Cyclic Peptide Nanotubes for the Delivery of Doxorubicin into Drug-Resistant Cancer Cells, ACS Applied Materials & Interfaces.